Silvia Fargion

Q: What Schools Are Affiliated With Silvia Fargion

Silvia Fargion is affiliated with the following schools: University of Trieste, University of Milan, University of Trento, University of Florence

Silvia Fargion's AcademicInfluence.com Rankings

Silvia Fargion

Physics

#7507

World Rank

#9541

Historical Rank

Particle Physics

#388

World Rank

#406

Historical Rank

physics Degrees

Download Badge

Physics

Silvia Fargion's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Silvia Fargion Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Silvia Fargion's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes (2008) (617)
Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease (2010) (573)
The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. (2016) (476)
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease (2015) (424)
Statin use and non-alcoholic steatohepatitis in at risk individuals. (2015) (288)
PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells (2014) (285)
Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association (1992) (285)
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. (2010) (283)
Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study (2007) (277)
I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease (2010) (269)
Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. (2011) (265)
Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. (2010) (261)
Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease (2002) (261)
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. (2010) (255)
Patatin‐Like phospholipase domain‐containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C (2011) (244)
Heterogeneity of hemochromatosis in Italy. (1998) (241)
Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non–iron‐related chronic liver disease (2001) (229)
Carotid artery intima-media thickness in nonalcoholic fatty liver disease. (2008) (214)
Surival and prognostic factors in 212 Italian patients with genetic hemochromatosis (1992) (199)
High prevalence of the His63Asp HFE mutation in italian patients with porphyria cutanea tarda (1998) (195)
Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. (2003) (182)
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals (2017) (180)
Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. (2014) (178)
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis (2001) (174)
Natural history of juvenile haemochromatosis (2002) (159)
Association between iron overload and osteoporosis in patients with hereditary hemochromatosis (2008) (158)
The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. (2012) (152)
Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis (2008) (149)
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease (2010) (149)
Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. (2008) (148)
Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. (2002) (147)
Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity (2017) (135)
Dietary iron overload induces visceral adipose tissue insulin resistance. (2011) (131)
Bone and joint involvement in genetic hemochromatosis: role of cirrhosis and iron overload. (1997) (119)
A population-based study on the prevalence of NASH using scores validated against liver histology. (2014) (119)
Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. (2008) (118)
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B (2012) (118)
Prognostic factors for hepatocellular carcinoma in genetic hemochromatosis (1994) (114)
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. (2011) (110)
Dietary Anthocyanins as Nutritional Therapy for Nonalcoholic Fatty Liver Disease (2013) (109)
Liver fat accumulation is associated with circulating PCSK9 (2016) (107)
Monoclonal antibodies that distinguish non-small cell from small cell lung cancer. (1983) (106)
Procoagulant imbalance in patients with non-alcoholic fatty liver disease. (2014) (103)
MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. (2016) (98)
Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. (2001) (95)
Contrast‐enhanced doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis (2001) (94)
Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. (2018) (90)
The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage (2016) (90)
Serum Hepcidin and Macrophage Iron Correlate With MCP-1 Release and Vascular Damage in Patients With Metabolic Syndrome Alterations (2011) (90)
miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis (2018) (88)
Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. (2009) (88)
Increased susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary hemochromatosis. (2003) (87)
The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients (1996) (86)
Iron and insulin resistance (2005) (86)
α1‐Antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage (2006) (85)
Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. (2009) (85)
Searching for coeliac disease in patients with non-alcoholic fatty liver disease. (2004) (85)
A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. (2014) (84)
A point mutation in the bulge of the iron-responsive element of the L ferritin gene in two families with the hereditary hyperferritinemia-cataract syndrome. (1998) (83)
Procoagulant imbalance in patients with non-alcoholic fatty liver disease. (2014) (82)
Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma (2011) (81)
Iron reduction and sustained response to interferon-α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study (2002) (80)
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. (2011) (80)
Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. (2011) (79)
Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: polygraphic and echocardiographic evaluation. (1991) (79)
Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease (2017) (79)
The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis (2004) (79)
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease (2019) (77)
Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. (2016) (76)
Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. (2001) (75)
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease (2013) (75)
Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease (2012) (75)
Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. (1992) (72)
Liver iron influences the response to interferon alpha therapy in chronic hepatitis C (1997) (72)
The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease? (2009) (71)
Specific binding sites for H-ferritin on human lymphocytes: modulation during cellular proliferation and potential implication in cell growth control. (1991) (71)
Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. (2011) (69)
Haemochromatosis in patients with β‐thalassaemia trait (2000) (68)
Liver iron concentration in chronic viral hepatitis: a study of 98 patients (1995) (67)
Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. (2007) (67)
Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD (2016) (65)
Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant. (2015) (65)
Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. (2001) (65)
Immunohistochemical evidence for a lack of ferritin in duodenal absorptive epithelial cells in idiopathic hemochromatosis. (1989) (63)
Iron-dependent regulation of MDM2 influences p53 activity and hepatic carcinogenesis. (2010) (63)
Functional roles of the ferritin receptors of human liver, hepatoma, lymphoid and erythroid cells. (1992) (63)
LPIN1 rs13412852 Polymorphism in Pediatric Nonalcoholic Fatty Liver Disease (2012) (62)
The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls (2012) (62)
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease (2016) (61)
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. (2019) (61)
The hand arthropathy of hereditary hemochromatosis is strongly associated with iron overload. (2008) (61)
Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study (2010) (61)
Patatin‐like phospholipase domain‐containing 3 I148M affects liver steatosis in patients with chronic hepatitis B (2013) (61)
Inherited HFE‐unrelated hemochromatosis in italian families (1999) (60)
Beta-globin mutations are associated with parenchymal siderosis and fibrosis in patients with non-alcoholic fatty liver disease. (2010) (60)
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis (2015) (60)
Relationship between TNF‐α and iron metabolism in differentiating human monocytic THP‐1 cells (2000) (60)
Hepatic iron is the major determinant of serum ferritin in NAFLD patients (2018) (58)
Heterogeneity of cell surface antigen expression of human small cell lung cancer detected by monoclonal antibodies. (1986) (58)
Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients (2015) (57)
Synergies and tensions in child protection and parent support: policy lines and practitioners cultures (2014) (57)
Iron metabolism in thalassemia intermedia. (1990) (56)
Non-transferrin-bound iron in alcohol abusers. (2001) (53)
Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease. (2017) (53)
Characteristics and expression of binding sites specific for ferritin H-chain on human cell lines. (1988) (51)
PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma (2013) (50)
Liver fibrosis by FibroScan® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes (2020) (46)
Hemochromatosis gene (HFE) mutations and cancer risk: Expanding the clinical manifestations of hereditary iron overload (2010) (46)
Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. (2004) (45)
Effect of iron depletion in patients with nonalcoholic fatty liver disease without carbohydrate intolerance. (2003) (45)
Carbohydrate‐deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron (1999) (45)
High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload (2015) (45)
PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans (2017) (45)
The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease (2012) (45)
Mutations in the HFE gene and their interaction with exogenous risk factors in hepatocellular carcinoma. (2001) (45)
Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: possible explanation for iron overload. (1996) (44)
Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis. (2012) (44)
The UCP2 ‐866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. (2015) (43)
127 HOMOZYGOSITY FOR THE PNPLA3/ADIPONUTRIN I148M POLYMORPHISM INFLUENCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2010) (42)
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease (2017) (42)
Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. (2012) (41)
Portal hypertension and iron depletion in patients with genetic hemochromatosis (1993) (41)
Hemochromatosis in Italy in the last 30 years: Role of genetic and acquired factors (2010) (41)
Fibronectin Type III Domain–Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2017) (40)
A promoter polymorphism in the liver-specific fatty acid transport protein 5 is associated with features of the metabolic syndrome and steatosis. (2010) (40)
Carbohydrate-deficient transferrin, a sensitive marker of chronic alcohol abuse, is highly influenced by body iron. (1999) (40)
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age‐dependent risk profiling study (2017) (40)
Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease (2016) (40)
Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin (2012) (39)
Brain involvement in non-alcoholic fatty liver disease (NAFLD): A systematic review. (2019) (39)
TNFα genotype affects TNFα release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis (2005) (38)
HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients. (2009) (38)
Linkage analysis of 6p21 polymorphic markers and the hereditary hemochromatosis: localization of the gene centromeric to HLA-F. (1993) (37)
Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects (2013) (37)
Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease (2018) (37)
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients[S] (2019) (36)
Risk of Obstructive Sleep Apnea with Daytime Sleepiness Is Associated with Liver Damage in Non-Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease (2014) (35)
Prevalence of idiopathic hemochromatosis in Italy: study of 1301 blood donors. (1990) (35)
Hepcidin resistance in dysmetabolic iron overload (2015) (35)
Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. (2016) (35)
Relationship between TNF-alpha and iron metabolism in differentiating human monocytic THP-1 cells. (2000) (34)
Virological Profiles in Hepatitis B Virus/Hepatitis C Virus Coinfected Patients under Interferon plus Ribavirin Therapy (2006) (34)
Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. (2012) (33)
DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection (2015) (32)
Iron Stores, Hepcidin, and Aortic Stiffness in Individuals with Hypertension (2015) (32)
CYBRD1 as a modifier gene that modulates iron phenotype in HFE p.C282Y homozygous patients (2012) (32)
Reflections on social work's identity (2008) (32)
Consensus recommendations for managing asymptomatic persistent non-virus non-alcohol related elevation of aminotransferase levels: suggestions for diagnostic procedures and monitoring. (2008) (32)
A tetra‐primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype (2011) (31)
Association of hereditary spherocytosis and idiopathic hemochromatosis. A synergistic effect in determining iron overload. (1986) (31)
Preclinical hypogonadism in genetic hemochromatosis in the early stage of the disease: evidence of hypothalamic dysfunction (1992) (31)
Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. (2004) (30)
AISF position paper on liver disease and pregnancy. (2016) (30)
Association between heterozygosity for HFE gene mutations and hepatitis viruses in hepatocellular carcinoma. (2005) (30)
Iron overload in subjects with beta‐thalassaemia trait: role of idiopathic haemochromatosis gene (1985) (28)
Identification of two novel mutations in the 5'-untranslated region of H-ferritin using denaturing high performance liquid chromatography scanning. (2003) (28)
Iron overload in porphyria cutanea tarda. (1999) (27)
Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin‐A independently of insulin resistance (2014) (27)
Peripheral lymphocytes and intracellular cytokines in C282Y homozygous hemochromatosis patients. (2002) (26)
Clinical, biochemical and histological features of primary haemochromatosis: a report of 67 cases. (2008) (26)
755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS (2013) (26)
Serum marker of type III procollagen in patients with idiopathic hemochromatosis and its relationship to hepatic fibrosis. (1983) (25)
Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. (2021) (24)
No association between genetic hemochromatosis and α1‐antitrypsin deficienc (1996) (24)
The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis (2013) (24)
Desferrioxamine Loading of Red Cells for Transfusion (1987) (23)
Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study (2016) (23)
TM6SF2 Gene Variant Disentangles Nonalcoholic Steatohepatitis from Cardiovascular Disease (2014) (23)
Prevalence of hepatitis C virus infection in porphyria cutanea tarda. (2003) (23)
Role of iron in hepatocellular carcinoma (2014) (22)
TT virus infection in adult beta-thalassemia major patients. (2001) (21)
Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. (2017) (20)
TNFalpha genotype affects TNFalpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. (2005) (20)
Erythrocyte ferritin in thalassemia syndromes. (1984) (20)
Idiopathic haemochromatosis and HLA antigens in Italy: is A3 Bw35 HLA haplotype a marker for idiopathic haemochromatosis gene in north east regions? (1986) (20)
Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease (2020) (19)
Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C. (2011) (19)
Dysmetabolic hyperferritinemia and dysmetabolic iron overload syndrome (DIOS): two related conditions or different entities? (2020) (18)
Treatment choices for people infected with HCV. (2004) (18)
Red blood cell antioxidant and iron status in alcoholic and nonalcoholic cirrhosis (2002) (18)
Thinking Professional Social Work (2006) (18)
98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B (2010) (18)
OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCE (2011) (17)
Early iron overload in beta-thalassaemia major: when to start chelation therapy? (1982) (17)
Iron in the pathogenesis of hepatocellular carcinoma. (1991) (17)
HFE Gene Mutations and Oxidative Stress Influence Serum Ferritin, Associated with Vascular Damage, in Hemodialysis Patients (2007) (17)
Saturability of hepatic iron deposits in genetic hemochromatosis (1992) (16)
Social work promoting participation: reflections on policy practice in Italy (2018) (16)
Seven novel point mutations in the uroporphyrinogen decarboxylase (UROD) gene in patients with familial porphyria cutanea tarda (f‐PCT) (2001) (16)
HFE mutations in nonalcoholic fatty liver disease (2008) (15)
TNFα Promoter Polymorphisms (2004) (15)
Liver transplantation for hepatocellular carcinoma in a patient with a novel telomerase mutation and steatosis. (2013) (15)
Binding and suppressive activity of human recombinant ferritins on erythroid cells (1992) (15)
Iron and liver diseases. (2000) (15)
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. (2019) (15)
Research with social workers to improve their social interventions (2011) (15)
PREVALENCE AND CLINICAL SIGNIFICANCE OF HEPATITIS G VIRUS INFECTION IN ADULT BETA‐THALASSAEMIA MAJOR PATIENTS (1997) (15)
Developing Entrepreneurship in Social Work Through International Education. Reflections on a European Intensive Programme (2011) (15)
Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. (2019) (15)
Nontransfusional iron overload in thalassemia intermedia: role of the hemochromatosis allele. (1998) (14)
Alcohol Dehydrogenase: An Autoantibody Target in Patients with Alcoholic Liver Disease (2005) (14)
Non-specific iron in patients with beta-thalassaemia trait and chronic active hepatitis. (2009) (14)
What is the contribution of differences in three measures of tumor necrosis factor-alpha activity to insulin resistance in healthy volunteers? (2003) (13)
Sustained response to combination therapy in patients with chronic hepatitis C who failed to respond to interferon. (2003) (13)
High prevalence of hepatitis C virus type 1b in Italian patients with Porphyria cutanea tarda. (1997) (13)
HLA typing in 67 Italian patients with idiopathic hemochromatosis and their relatives. (1989) (13)
Characteristics of the membrane receptor for human H-ferritin. (1991) (13)
Comparable frequency of hepatocellular carcinoma in cirrhosis of different aetiology (1994) (12)
α1‐Antitrypsin in patients with hepatocellular carcinoma and chronic active hepatitis (1981) (12)
Characteristics and expression of binding sites specific for ferritin H- chain on human cell lines (1988) (11)
Subclinical cerebrovascular disease in NAFLD without overt risk factors for atherosclerosis. (2018) (11)
Hemochromatosis: Thalassemias and their interactions with hemochromatosis (2000) (11)
HFE Genotype Influences Erythropoiesis Support Requirement in Hemodialysis Patients: A Prospective Study (2007) (11)
Immunohistochemistry of HFE in the duodenum of C282Y homozygotes with antisera for recombinant HFE protein. (2000) (11)
Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda (2001) (10)
Chronic liver disease in transfusion-dependent thalassaemia: hepatitis B virus marker studies. (1980) (10)
The iron status of Italian subjects with beta-thalassemia trait. (1982) (10)
Hereditary hemochromatosis in a patient with congenital dyserythropoietic anemia. (2000) (10)
T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment (2012) (10)
Molecular analysis of the hydroxymethylbilane synthase (HMBS) gene in Italian patients with acute intermittent porphyria: Report of four novel mutations (2000) (10)
522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY (2012) (10)
Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of HFE Gene Mutations (2008) (10)
FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage (2020) (9)
Liver involvement in Gaucher disease: A practical review for the hepatologist and the gastroenterologist. (2020) (9)
IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: A multicenter prospective trial in Italy (2018) (9)
Evaluation of T and B lymphocytes in liver infiltrates of patients with chronic active hepatitis. (1979) (9)
NONTRANSFUSIONAL IRON OVERLOAD IN THALASSEMIA INTERMEDIA : ROLE OF THE HEMOCHROMATOSIS ALLELE (1998) (9)
F.N.16 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (9)
1280 DIETARY IRON OVERLOAD INDUCES VISCERAL ADIPOSE TISSUE INSULIN RESISTANCE ASSOCIATED WITH HYPER-RESISTINEMIA, AND SYNERGIZES WITH OBESITY AND FATTY LIVER IN INDUCING SYSTEMIC INSULIN RESISTANCE (2011) (9)
Detection of hepatitis C virus by polymerase chain reaction and recombinant immunoblot assay 3.0 in porphyria cutanea tarda (1995) (9)
Patatin‐like phospholipase domain containing‐3 Ile148Met and fibrosis progression after liver transplantation (2011) (8)
Mutations of the hemochromatosis gene in Italian candidate blood donors with increased transferrin saturation. (2003) (8)
NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. (2020) (8)
GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. (2017) (8)
‘A Community no matter what’: fostering social work professional connections in Italy in COVID-19 times (2020) (8)
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis (2019) (8)
Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C (2014) (8)
89 Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non-alcoholic fatty liver disease: A case control study (2006) (8)
HCV-related mixed cryoglobulinemia: Data from PITER, a nationwide Italian HCV cohort study (2016) (8)
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC (2021) (8)
HCV type 1b in patients with chronic liver diseases and porphyria cutanea tarda (PCT) (1995) (7)
Lack of association between porphyria cutanea tarda and α1,-antitrypsin deficiency (1996) (7)
Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors. (2014) (7)
Risk of early atherosclerosis evaluated by carotid artery intima-media thickness in patients with non-alcoholic fatty liver disease : a case control study (2006) (7)
1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (7)
EFFECTIVENESS OF ENTECAVIR FOR THE TREATMENT OF NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS: A LARGE MULTICENTER COHORT STUDY IN CLINICAL PRACTICE (2009) (7)
Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. (2020) (7)
Dysmetabolic iron overload syndrome. (1999) (7)
GNPAT p.D519G variant and iron metabolism during oral iron tolerance test (2017) (7)
14 A DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION (2010) (7)
Analysis of the genes for transferrin, transferrin receptor as well as H and L subunits of ferritin in idiopathic hemochromatosis (1987) (7)
Extrapulmonary tuberculosis: an unusual presentation in an immunocompetent patient (2015) (7)
Lack of association between peroxisome proliferator-activated receptors alpha and gamma 2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease : a case control study (2010) (7)
No association between genetic hemochromatosis and alpha1-antitrypsin deficiency. (1996) (7)
Severe and prolonged jaundice in a lupus nephritis patient treated with cyclophosphamide. (1997) (6)
Combined use of genetic polymorphisms and elastographic techniques in NAFLD. Fact or fiction? (2019) (6)
Increased circulating adiponectin in males with chronic HCV hepatitis. (2015) (6)
A novel alpha1-antitrypsin null variant (PiQ0Milano ). (2013) (6)
Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter study (2012) (6)
Interleukin 28B Genotype and Insulin Resistance in Chronic Hepatitis C Patients (2014) (6)
1194 End of treatment and sustained response to peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) (COPEGUS) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2A (ROFERON-A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) (2003) (6)
Molecular analysis of the TFR2 gene: Report of a novel polymorphism (1878C>T) (2000) (6)
399 PNPLA3 I148M AFFECTS LIVER STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS B (2013) (6)
18 DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION (2010) (6)
Images of Contract: An Empirical Study of the Use of Theory in Practice (2003) (6)
Levels of uroporphyrinogen decarboxylase (URO-D) in erythrocytes of Italian porphyria cutanea tarda patients. (2002) (6)
Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown (2022) (6)
Triple antiviral therapy in HCV positive patients who failed prior combination therapy. (2006) (6)
Fargion-Synergies and tensions in child protection 1 Synergies and tensions in child protection and parent support : Insights from the Italian case (2007) (5)
730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS (2011) (5)
475 Sustained virological response (SVR) to peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (Roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC) (2004) (5)
Risk of severe liver disease in nonalcoholic fatty liver disease: Role of insulin resistance (2008) (5)
Patatin‐like phospholipase domain‐containing protein 3 genotype and hepatocellular carcinoma in chronic hepatitis C (2011) (5)
Protein Phosphatase 1 Regulatory Subunit 3 B Gene Variation Protects Against Hepatic Fat Accumulation and Fibrosis in Individuals at High Risk of Nonalcoholic Fatty Liver Disease (2018) (5)
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. (2019) (5)
GNPAT rs11558492 is not a Major Modifier of Iron Status: Study of Italian Hemochromatosis Patients and Blood Donors. (2017) (5)
Can large cell change and high proliferative activity predict hepatocellular carcinoma in patients with hereditary hemochromatosis (2000) (5)
IMMUNOLOGICAL REACTIVITY IN BETA-THALASSÆMIA (1975) (4)
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients patient-oriented and epidemiological research (2020) (4)
Acquired hepatocerebral degeneration (AHD): a peculiar neurological impairment in advanced chronic liver disease (2018) (4)
PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease (2022) (4)
315 I148M PNPLA3 POLYMORPHISM IS ASSOCIATED WITH CLINICAL FEATURES IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (2012) (4)
The relevance of immune reactions in acute favism. (1974) (4)
Alpha 1-antitrypsin in patients with hepatocellular carcinoma and chronic active hepatitis. (1981) (4)
Impact of natural neuromedin‐B receptor variants on iron metabolism (2019) (4)
TNFalpha promoter polymorphisms. (2004) (4)
Rosette inhibition test in chronic liver disease. (1976) (4)
524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS (2012) (4)
Oxidative Stress and Hepatic Iron Overload (2015) (4)
Iron as risk factor for hepatocellular carcinoma (1998) (4)
Access to social services as a rite of integration: Power, rights, and identity (2018) (4)
Ferroportin-1 in the recurrence of hepatic iron overload after liver transplantation. (2009) (4)
Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. (2006) (4)
Peginterferon alfa-2A (40KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2A (roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) (2003) (4)
Siderosis in cirrhosis: is genetic hemochromatosis ruled out? (1998) (3)
Clients’ Participation and Social Work Practices : The Case of the Contract between Client and Practitioner (2016) (3)
Negotiating Quality for Social Work: A Participatory Research Project in South Tyrol (2020) (3)
Ronald J. Angel, Laura Lein e Jane Henrici, Poor Families in America's Health Crisis. How the Other Half Pays (2008) (3)
Representations of parenting and the neo-liberal discourse: parents’ and professionals’ views on child-rearing practices in Italy (2021) (3)
[Cellular immunity in intra- and extra-hepatic cholestasis]. (1976) (3)
[769] IRON DEPLETION BY PHLEBOTOMY IMPROVES INSULIN RESISTANCE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE AND HYPERFERRITINEMIA; EVIDENCE FROM A CASE CONTROL STUDY (2007) (3)
Adiponectin in nonalcoholic fatty liver disease : correlation with liver damage and PNPLA3 genotype (2011) (3)
P0340 : Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): A multicenter case-control study (2015) (3)
FibroScan Detects Cardiovascular Damage in Patients With NAFLD. (2018) (3)
Theory and Practice: A Matter of Words. Language, Knowledge and Professional Community in Social Work (2007) (3)
T AND B LYMPHOCYTES IN HUMAN SPLEEN (1974) (3)
HCV–Related Mixed Cryoglobulinemia: Data from Piter, a Nationwide Italian HCV Cohort Study (2016) (3)
Iron depletion by phlebotomy improves insulin resistance in patients with non alcoholic fatty liver disease and hyperferritinemia ; evidence from a multicenter case control study (2007) (3)
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. (2019) (3)
Can nonalcoholic steatohepatitis trigger porphyria cutanea tarda clinical manifestations? (2009) (3)
FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver (2019) (3)
Gender Differences in HCV Chronic Liver Disease: A Real Life Evaluation in Piter (Piattaforma Italiana per Lo Studio Della Terapia Delle Epatiti Virali) Cohort Study (2016) (3)
High prevalence of early atherosclerotic and cardiac damage in patients undergoing liver transplantation: Preliminary results. (2019) (3)
Iron genes, dysmetabolism and fibrosis in chronic hepatitis C. (2008) (3)
916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY (2009) (2)
T‐ARMS‐PCR for the evaluation of rs12979860 IL28B genotype: an optimized protocol (2012) (2)
MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver (2016) (2)
Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease (NAFLD): a multicenter case-control study (2015) (2)
F-17 Dietary iron overload induces visceral adipose tissue insulin resistance and hyper-resistinemia, and synergizes with obesity and fatty liver in inducing systemic insulin resistance (2011) (2)
OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS (2010) (2)
IL28B rs12979860 polymorphism influences serum TNFalpha levels in chronic hepatitis C. (2013) (2)
602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY (2009) (2)
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study (2006) (2)
Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study (2018) (2)
Heart failure and chronic kidney disease in a registry of internal medicine wards (2014) (2)
Hepatic iron concentration and total body iron burden in genetic hemochromatosis (GH) (1991) (2)
T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC (2013) (2)
TNFalpha promoter polymorphisms in Italian patients with porphyria cutanea tarda. (2003) (2)
Liver iron distribution, histological activity and mutations in the hemochromatosis gene (HFE) in chronic hepatitis C (1998) (2)
FOXO1 genotype influences the susceptibility to and severity of NAFLD by modulating FOXO1 expression (2009) (2)
A novel polymorphism (219G>A) in the transferrin receptor gene (2000) (2)
Prevalence of cholelithiasis in alcoholic and genetic haemochromatotic cirrhosis. (1993) (2)
Relative contribution of iron genes, dysmetabolism and hcv in the pathogenesis of altered iron regulation in chronic hepatitis C (2007) (2)
Combination of interferon alpha and ribavirin in chronic hepatitis C non responders to interferon monotherapy: role of genotype and age (2001) (2)
A recombination event close to HFE gene in hereditary hemochromatosis. (1997) (2)
Acculturation theory, cultural competency and learning from differences: reflections from a European short student mobility program (2020) (1)
A distinct miRNA expression profile in hepatocellular carcinoma arising in carriers of the I148M PNPLA3 gene variant (2015) (1)
PCSK9 deficiency results in altered glucose control and increased ectopic fat accumulation in experimental models and in humans (2018) (1)
TNFalpha promoter polymorphisms and insulin resistance in HCV-related liver disease (2003) (1)
Variant is Associated with Liver Damage in Patients with Non-alcoholic Fatty Liver Disease (2017) (1)
Lack of association between porphyria cutanea tarda and alpha 1-antitrypsin deficiency. (1996) (1)
Clinical Determinants of Fibrosis Progression in an Italian Prospective Cohort of Patients with Non-Alcoholic Fatty Liver Disease (2016) (1)
872 ADIPONECTIN IN NONALCOHOLIC FATTY LIVER DISEASE: CORRELATION WITH LIVER DAMAGE AND PNPLA3 GENOTYPE (2011) (1)
SAT-314-Liver fibrosis by FibroScan is highly prevalent in type 2 diabetic patients with NAFLD and fairly normal liver enzymes but increased uric acid (2019) (1)
96 IRON DEPLETION BY DEFEROXAMINE UPREGULATES GLUCOSE UPTAKE AND INSULIN SIGNALING IN HEPATOCYTES AND IN A RAT MODEL OF FATTY LIVER (2008) (1)
Theories and practices in social work : practitioners' representations of contract work (2001) (1)
Staphylococcus haemolyticus superinfection of legionella pneumonia during infliximab therapy (2011) (1)
Increased prevalence of PiS alpha 1-antitrypsin allele in Italian patients with non alcoholic fatty liver disease (2005) (1)
T-12 Echocardiographic epicardial fat thickness in non alcoholic fatty liver disease: A possible marker of metabolic syndrome and early vascular damage (2011) (1)
377 BETA-GLOBIN MUTATIONS ARE ASSOCIATED WITH PARENCHYMAL SIDEROSIS AND FIBROSIS SEVERITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2010) (1)
Cardiovascular involvement after liver transplantation: role of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (2021) (1)
FibroScan stiffness and CAP in the evaluation of cardiovascular risk assessment in patients with NAFLD (2018) (1)
Liver fat accumulation is associated with circulating PCSK9 levels (2015) (1)
MAFLD AND NAFLD: is there the need for redefining the risk of cardiovascular disease and mortality? (2021) (1)
Hepatocellular carcinoma and non malignant lesions in cirrhotic liver: assessment with contrast-enhanced Doppler ultrasonography (2001) (1)
Letter: Antibodies to mitochondria in intrahepatic and extrahepatic cholestasis. (1974) (1)
Can large cell change and high proliferative activity predict hepatocellular carcinoma in patients with hereditary hemochromatosis? (2000) (1)
FNDC5 rs3480 A>G polymorphism disentangles steatosis from fibrosis severity in patients with nonalcoholic fatty liver disease (2016) (1)
Insulin resistance and tnf alpha polymorphism in Italian patients with non alcoholic fatty liver disease (NAFLD) (2001) (1)
Lysosomal acid lipase activity is reduced in NAFLD: Mechanisms and rescue by PPAR-alpha agonists (2018) (1)
Progressively invalidating orthostatic hypotension: A common symptom for a challenging diagnosis (2016) (1)
Iron depletion and interferon (IFN) therapy: A multicenter, randomized trial in “naive” patients with chronic hepatitis C (2000) (1)
NTBI is present in chronic alcohol abusers (2000) (1)
patients with non-alcoholic fatty liver disease are associated with the severity of liver damage in Genetic variants regulating insulin receptor signalling (1)
O071 : Telomerase reverse transcriptase mutations are associated with hepatocellular carcinoma in nash (2015) (1)
Mutations in the hemochromatosis gene and response to interferon in chronic hepatitis C (1998) (1)
Food quality, effects on health and sustainability today: a model case report (2017) (1)
Obstructive sleep apnea syndrome in non-severely obese patients with NAFLD (2014) (1)
[Lymphocyte typing in chronic hepatopathies]. (1976) (0)
372 CONTRAST-ENHANCED ULTRASONOGRAPHY (CEUS) AND SPIRAL COMPUTED TOMOGRAPHY (CT) IN THE ASSESSMENT OF EFFICACY OF PERCUTANEOUS ABLATION TREATMENTS OF HEPATOCELLULAR CARCINOMA IN CIRRHOSIS (2008) (0)
Diagnostic flow-chart in haemochromatosis (2005) (0)
Chronic liver disease intransfusion-depe ndent thalassaemia: hepatitis Bvirus marker studies (1980) (0)
OC-17 The A736V TMPRSS6 polymorphism is associated with the penetrance of hereditary hemochromatosis and hepatocellular carcinoma in C282Y+/+ patients (2012) (0)
Correction: High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload (2015) (0)
P744 DEPDC5 GENE LOCUS ASSOCIATES WITH SEVERE LIVER FIBROSIS IN INDIVIDUALS WITH CHRONIC HCV INFECTION (2014) (0)
Lean-Non-Alcoholic Fatty Liver Disease with Central Visceral Obesity Identifies Patients with More Severe Disease (2016) (0)
Serum ferritin, is associated with iron availability, decreased anti-oxidant potemtial and HFE gene mutations, and a risk factor for cardiovascular damage in hemodialysis patients (2007) (0)
Non alcoholic fatty liver disease in Italy: a multicenter study (2001) (0)
Cytotoxic T-lymphocyte antigen 4 is associated with development and progression of alcoholic liver disease (ALD) in Italian patients (2002) (0)
Research synergies in social professions (2008) (0)
PS-005-Evaluation of neuromedin-B receptor variants effect on iron metabolism and liver disease (2019) (0)
Different levels of uroporphyrevogen decarboxylase (URO-D) activity in erythrocytes of porphyria cutanea tarda patients (2000) (0)
Effectiveness of regular surveillance for hepatocellular carcinoma in patients with hemochromatosis and cirrhosis: A study of 70 cases (2000) (0)
Impaired renal function but high sustained virological response (SVR) rates in hepatitis C virus (HCV) elderly treated with direct-acting antivirals (DAA): A report from the Lombardy Network (2018) (0)
63 Hepatic expression of the forkhead transcription factor foxO1 is increased in non-alcoholic steatohepatitis and associated with gluconeogenesis and insulin resistance (2006) (0)
Fibroscan liver stiffness (LMS) and controlled attenuation parameter (CAP) in the evaluation of cardiovascular risk assessment in patients with NAFLD (2018) (0)
[94] RISK OF EARLY ATHEROSCLEROSIS BY CAROTID ARTERY INTIMA-MEDIA THICKNESS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE AND LOW VISCERAL ADIPOSITY (2009) (0)
Prevalence of sarcopenia and cardiovascular alterations in a cohort of non-cirrhotic MAFLD patients (2022) (0)
Non-transferrin-bound iron (NTBI) is present in chronic alcohol abusers with and without liver cirrhosis during active alcohol abuse (2000) (0)
The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin (2009) (0)
Non-specific serum iron in patients with thalassaemia trait and chronic liver disease (1979) (0)
Differential patterns of contrast-enhancement ultrasonography with SonoVue in small focal lesions arisng in cirrhosis (2006) (0)
Sustained virological response (SVR) to peginterferon alfa-2a (40 KD) (PEGASYS) plus ribavirin (RBV) and amantadine (AMA) Vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (2006) (0)
Impact of deterioration of lifestyle in nalfd patients during COVID-19 lockdown (2021) (0)
MERTK rs4374383 AA genotype is associated with a lower prevalence of severe hepatic steatosis in non-alcoholic fatty liver disease (2014) (0)
Functional characterization of a novel genetic variant predisposing to hepatocellular carcinoma development in nonalcoholic fatty liver disease (2018) (0)
Alcohol-related appearance of Non-Transferrin-Bound Iron (NTBI) in chronic alcohol abusers with cirrhotic and noncirrhotic liver disease (2000) (0)
Role of rare pathogenic mutations in the development of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease (2018) (0)
P816 MERTK rs4374383 AA GENOTYPE IS ASSOCIATED WITH A LOWER PREVALENCE OF SEVERE HEPATIC STEATOSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (0)
Letter: Immunological reactivity in beta-thalassaemia. (1975) (0)
THU-335-FXR rs35724 C >G variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver (2019) (0)
Insulin related early andothelial dysfuction in patients with non alcoholic fatty liver disease (NAFLD) (2006) (0)
Results Risk-Associated HFE Genotypes Influence Iron Handling , But Not Oxidative Stress , in Differentiating Human Monocytes of Patients With Hyperferritinemia (2010) (0)
Letter: T and B lymphocytes in human spleen. (1974) (0)
Evaluation of antinuclear antibody (ANA) by a microfluorometric reference ‘numerical’ scale applied to sera from patients with autoimmune liver disease (1975) (0)
P179Absence of cardiac siderosis at cardiac magnetic resonance in patients with dysmetabolic hyperferritinemia (2019) (0)
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals (2017) (0)
1042 Mitochondrial superoxide dismutase ALA9VAL polymorphism and phenotypic expression of hereditary hemochromatosis (2003) (0)
Erratum: (Journal of Viral Hepatitis) (2014) (0)
Iron overload, hfe gene mutations and insulin resistance in non alcoholic fatty liver disease (NAFLD) (2002) (0)
Iron overload impairs the migratory ability of a model of immature and migratory GnRH neurons (2013) (0)
[Aspects of humoral immunity in ulcerous colitis]. (1975) (0)
TNF alpha polymorphisms, HFE gene mutations and acquired factors in Italian patients with porphyria cutanea tarda (2002) (0)
Risk of NASH and severe fibrosis in patients with NAFLD and low visceral adiposity (2009) (0)
Treatment of chronic hepatitis C in Lombardia: An analysis on the safety and efficacy of DAA therapy in 5457 patients (2017) (0)
Evaluation of cellular immunity in chronic liver diseases during immunosuppressive treatment. (1974) (0)
Molecular Pathogenesis of Hemochromatosis (1996) (0)
Clinical determinants of fibrosis progression in an Italian prospective cohort of patients with nonalcoholic fatty liver disease (2016) (0)
Pulmonary involvement complicating plasma cell proliferative disorders: a case report and review of the literature (2012) (0)
1362 RISK OF OBSTRUCTIVE SLEEP APNEA SYNDROME AND ASSOCIATION WITH LIVER DAMAGE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE WITHOUT SEVERE OBESITY (2013) (0)
An update of the genetic status of the 55 Italian hemochromatosis patients with incomplete or negative HFE genotypes (2002) (0)
Coagulation imbalance is associated with hepatic fibrosis and vascular complications in patients with type2 diabetes and NAFLD (2022) (0)
Dispnea e leucocitosi, un’insolita diagnosi (2008) (0)
Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirintreatment in chronic hepatitis C (2011) (0)
CORRECTION OF ANAEMIA BY DESFERRIOXAMINE IN A PATIENT WITH ALCOHOLIC CIRRHOSIS (1988) (0)
Role of SERPINB3 like serological and molecular biomarker into NASH development and progression (2018) (0)
Increased expression and activity of the transcription factor foxol in non-alcoholic steatohepatitis (2007) (0)
Mutation and Polymorphism Report (2000) (0)
Epitope mapping of alcohol dehydrogenase in autoimmune hepatitis and alcoholic liver disease (2000) (0)
Independent predictors of CC-IMT progression over time (mm/year) in 63 patients with NAFLD from Northern Italy. (2013) (0)
[378] IRON STATUS MODULATES THE EXPRESSION OF THE UBIQUITIN LIGASE MDM-2 AND ITS TARGET p53 IN MOUSE HEPATOCYTES AND HUMAN MONOCYTES; EFFECT ON THE ANTI-OXIDANT RESPONSE (2007) (0)
903 INTERACTION BETWEEN THE PNPLA3 I148M MUTATION, BODY WEIGHT, AND STEATOSIS, IN DETERMINING THE PROGRESSION TO CIRRHOSIS IN HEREDITARY HEMOCHROMATOSIS (2011) (0)
918 PROGRESSION OF CAROTIC ATHEROSCLEROTIC DAMAGE IS RELATED TO ALT VALUES (2008) (0)
Baseline ALT and ferritin predict histological findings in NAFLD (2007) (0)
F-03Lean-non alcoholic fatty liver disease (NAFLD) with central visceral obesity identifies patients with more severe disease (2016) (0)
[710] REVISITATION OF A COHORT OF ITALIAN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS: CHANGES IN THE LAST THREE DECADES (2007) (0)
SAT-275-Interleukin-32 as a novel NAFLD biomarker in PNPLA31148M variant carriers (2019) (0)
Survival in patients with hepatocellular carcinoma and portal vein thrombosis (2016) (0)
Nonalcoholic fatty liver disease and vascular disease : State-ofthe-art WJG 20 th Anniversary Special Issues ( 12 ) : Nonalcoholic fatty liver disease (2014) (0)
Genotype 3 infection in DAA era: Preliminary reports of a real life northern Italy network for viral hepatitis (2016) (0)
1373 EFFECT OF IRON DEPLETION ON LIVER DAMAGE IN NONALCOHOLIC FATTY LIVER DISEASE: PRELIMINARY RESULTS OF A RANDOMIZED CONTROLLED TRIAL (2013) (0)
Reply (2010) (0)
Early menopausal status is associated with the severity of liver fibrosis in Italian patients with non-alcoholic fatty liver disease (2014) (0)
New onset steatosis but not persistent steatosis prevents hepatic fibrosis improvement after viral eradication by direct-acting antiviral therapy (DAAs) in patients with chronic hepatitis C: Evaluation by controlled attenuation parameter (CAP) and liver stiffness measurement LSM (2021) (0)
[Autoantibodies and Australia antigen in acute and chronic liver]. (1974) (0)
A novel three-step immunoscintigraphy employing an anti-ferritin antibody to detect hepatocellular carcinoma (1995) (0)
Revisitation of a cohort of 482 Italian patients with hereditary hemochromatosis: Changes in the last three decades (2007) (0)
Effect of iron depletion by phlebotomy on insulin resistance in patients with non alcoholic fatty liver disease and hyperferritinemia : evidence from a case control study (2007) (0)
T-31 Effect of the PNPLA3 I148M polymorphism on the outcome of peg-interferon plus ribavirin treatment in chronic hepatitis C (2012) (0)
T-21 Effect of iron depletion on liver damage in nonalcoholic fatty liver disease: preliminary results of a randomized controlled trial (2013) (0)
CTLA-4 recipient polymorphism influences HCV liver disease recurrence following orthotopic liver transplantation (OLT) (2002) (0)
Excellent effectiveness of direct-acting antivirals for HCV treatment in patients with cirrhosis: Analysis of 3345 patients from the Lombardia Network (2018) (0)
Unexpected very early atherosclerotic and cardiac damage in patients undergoing liver transplantation (2016) (0)
Evaluation of cellular immunity in chronic liver disease during corticosteroid therapy (1974) (0)
Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network (2018) (0)
[709] BASELINE ALT AND FERRITIN PREDICT HISTOLOGICAL FINDINGS IN NAFLD (2007) (0)
F-9 The I148M PNPLA3 polymorphism is associated with the clinical presentation and prognosis of hepatocellular carcinoma (2012) (0)
expression of hereditary hemochromatosis promoter polymorphisms influence the phenotypic α Tumor necrosis factor (2013) (0)
Could Iron Overload Impair the Migratory Ability of Neurons? Evidence from a Cell-Based Model (2012) (0)
Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis (2018) (0)
TNF alpha and hereditary hemocromatosis: possible interactions (2001) (0)
Learning Together: Care Leavers and Social Workers in a Project to Enhance Chances of Participation for Children in Care (2021) (0)
Gilbert ’ s syndrome (0)
FRI-256-Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage (2019) (0)
Reply: (2002) (0)
Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes (2019) (0)
Evaluation ofT andBlymphocytes inliver infiltrates ofpatients withchronic active hepatitis (1979) (0)
Liver transplantation (OLT) and cardiovascular risk: assessment of early atherosclerotic damage and metabolic disorders in patients undergoing liver transplantation (2015) (0)
Treatment of Iron Dependent Chronic Liver Disease (1993) (0)
deregulation of Fox01 and insulin signaling associated with steato hepatitis and hepatic insulin resistance (2007) (0)
Analisis of HLA-H mutations in italian patients with genetic hemochromatosis: Evidence of genetic heterogeneity (1997) (0)
Iron status modulates the expression of MDM-2, an ubiquitin ligase involved in p53 degradation; effect on the anti-oxidant response in hepatocytes (2007) (0)
Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group (2018) (0)
Frontline antiviral therapy in a series of HCV-related low grade non-Hodgkin lymphoma (2010) (0)
P858 EPICARDIAL FAT THICKNESS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS ASSOCIATED WITH MARKERS OF CARDIOVASCULAR DAMAGE AND SEVERITY OF STEATOSIS (2014) (0)
[100] INHERITED VARIANTS OF GENES INVOLVED IN INSULIN SIGNALING AND LIPOGENESIS INFLUENCE THE RISK OF HEPATIC FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE (2007) (0)
Histological variables predictive of hepatocellular carcinoma (HCC) in patients with genetic hemochromatosis (GH) (1998) (0)
FRI-333-ATG7 genetic variant and defective autophagy: A novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus (2019) (0)
Integrative analysis of NGS data highlight a genetic variant in ATG7 gene as a novel risk factor for nonalcoholic fatty liver disease progression (2018) (0)
GNPAT rs 11558492 is not a Major Modifier of Iron Status : Study of Italian Hemochromatosis Patients and Blood Donors (2017) (0)
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease (2019) (0)
A long story begun with a simple sore throat (2010) (0)
Reply: (2009) (0)
1397 ATYPICAL JUVENILE HEMOCHROMATOSIS ASSOCIATED WITH HETEROZYGOSITY FOR NOVEL HEMOJUVELIN MUTATIONS (2013) (0)
Impact of Neuromedin-B receptor variants on iron overload disorders (2018) (0)
OC6 A CRUCIAL CROSSROAD ON THE WAY TO LIVER TRANSPLANTATION (2011) (0)
Normal ALT should not preclude liver biopsy in patients with NAFLD (2008) (0)
T-11 Adiponectin in nonalcoholic fatty liver disease: Correlation with liver damage and PNPLA3 genotype (2011) (0)
Progression of carotic atherosclerotic damage is related to alt values in patients with non alcoholic fatty liver disease (2008) (0)
338 RISK OF EARLY ATHEROSCLEROSIS BY CAROTID ARTERY INTIMA-MEDIA THICKNESS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE AND LOW VISCERAL ADIPOSITY (2010) (0)
Effect of iron depletion by phlebotomy on insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia; results of a case control study (2007) (0)
Are the determinants of steatosis Associated with chronic hepatitis C( CHC) different from those of non alcoholic fatty liver disease ( NAFLD (2006) (0)
P271 INTERACTION BETWEEN DIETARY FACTORS AND INSULIN RESISTANCE IN THE PATHOGENESIS OF NONALCOHOLIC STEATOHEPATITIS (2014) (0)
260 ABERRANT METHYLATION OF ONCOSUPPRESSOR GENES DETECTED IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC HEPATITIS C AND HEPATOCELLULAR CARCINOMA (2011) (0)
P.09.24 ROLE OF SERPINB3 AND FIBROBLAST GROWTH FACTOR-21 IN THE PROGRESSION FROM NAFLD TO NASH (2018) (0)
Influence of iron on the specificity and sensitivity of carbohydrate-deficient transferrin (CDT) (1998) (0)
Liver function tests do not predict liver damage in diabetes. Analysis of liver steatosis and fibrosis by transient elastography in routine diabetes care (2018) (0)
702 IRON METABOLISM ALTERATIONS ASSOCIATED WITH HEPATIC IRON ACCUMULATION IN A DIETARY MODEL OF NONALCOHOLIC FATTY LIVER DISEASE (2009) (0)
PNPLA3/adiponutrin genotype is strongly associated with metabolic syndrome components and liver damage in patients with Nonalcoholic Fatty Liver Disease (2009) (0)
Autoantibodies to uroporphyrinogen decarboxylase in patients with porphyria cutanea tarda (1998) (0)
Liver, Pancreas and Bilary Tract I susceptibility to nonalcoholic fatty liver disease in heterozygotes for the mutation responsible for hereditary (2003) (0)
Coagulation balance and liver damage in non-cirrhotic patients with chronic hepatitis C after eradication by Direct-acting Antiviral Agents (DAAs) (2021) (0)
2 BETA-GLOBIN MUTATIONS ARE ASSOCIATED WITH PARENCHYMAL SIDEROSIS AND FIBROSIS SEVERITY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2010) (0)
F.N.39 HOMOZYGOSITY FOR THE PNPLA3/ADIPONUTRIN I148M POLYMORPHISM INFLUENCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2010) (0)
SGLT2 inhibitors improve hepatic fibrosis assessed by Fibroscan in NAFLD patients with type 2 diabetes: A five-year follow-up study (2023) (0)
OC-16 Interaction between the PNPLA3 I148M mutation and body weight in determining steatosis and the progression to cirrhosis in hereditary hemochromatosis (2011) (0)
P117 Preliminary report of a study on the the role of H63D mutation on iron overload in genetic hemochromatosis in Italy (2003) (0)
F-20 Risk of obstructive sleep apnea syndrome and association with liver damage in patients with nonalcoholic fatty liver disease without severe obesity (2013) (0)
Recreating gut-liver axis during NAFLD onset by using a Caco-2/HepG2 co-culture system (2022) (0)
dyserythropoietic anemia Hereditary hemochromatosis in a patient with congenital (2013) (0)
Progression of early atherosclerotic vascular damage in patients with NAFLD and in controls of general population during 10 years of follow up (2014) (0)
W11-P-003 Genetics of NAFLD: Role of cytokine polymorphisms (2005) (0)
18 TNFα promoter polymorphisms and insulin resistance in HCV-related fatty liver (2003) (0)
Genetic polymorphisms influencing insulin signalling and lipogenesis affect the risk of hepatic fibrosis in patients with nonalcoholic fatty liver disease (2007) (0)
35 INCREASED FERRITIN PREDICTS VASCULAR DAMAGE IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (2008) (0)
726 GENOTYPE OF THE TRANSCRIPTION FACTOR FOXO1 MEDIANTING INSULIN SIGNALING INFLUENCES THE SUSCEPTIBILITY TO AND SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE BY MODULATING FOXO1 MRNA LEVELS (2009) (0)
Prognostic factors in 216 patients with genetic hemochromatosis (GH) (1991) (0)
Metabolic syndrome and organ damage : NAFLD (2015) (0)
IFN alpha 2b and ribavirin in naive patients with HCV type 1 chronic hepatitis: results after 6 months of therapy (2001) (0)
Peripheral blood and liver tissue T and B lymphocytes and hepatitis B virus (HBV) (1978) (0)
Social work in a medical setting: reflection on inter-professional practice in a power imbalanced context (2017) (0)
Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis/compensated cirrhosis (2018) (0)
Iron affect glucose metabolismi in hepatocytes by regulating insulin receptor expression and glucose uptake (2006) (0)
Epicardial fat thickness (EAT) in patients with nonalcoholic fatty liver disease (NAFLD) is associated with markers of cardiovascular damage and severity of steatosis (2014) (0)
NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients (2020) (0)
Epidemiology and outcome of hepatocellular carcinoma in Lombardy (2007) (0)
The old patient in DAA era: Real life reports on 5925 patients from the Lombardy HCV Network (2017) (0)
Epicardial fat thickness is an ectopic fat associated with metabolic syndrome, subclinical atherosclerosis and markers of cardiac dysfunction in the general population (2015) (0)
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2010) (0)
Impact of Proprotein Convertase Subtilisin/Kexin Type 7 genetic variation in patients with non-alcoholic fatty liver disease (2018) (0)
Genetic factors and iron-related oxidative stress influence serum ferritin, associated with cardiovascular damage and mortality, in hemodialysis patients (2006) (0)
[770] ROLE OF TRB3 IN THE REGULATION OF HEPATIC LIPOGENESIS IN NONALCOHOLIC FATTY LIVER DISEASE (2007) (0)
Increased ferritin predicts vascular damage in patients with nonalcoholic fatty liver disease (2008) (0)
chronic active hepatitis . in liver infiltrates of patients with Evaluation of T and B lymphocytes (0)
919 EVALUATION OF PATIENTS WITH NAFLD WITH OR WITHOUT INCREASED ALT (2008) (0)
Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage (2019) (0)
911 Iron and insulin resistance: effect of iron manipulation on insulin receptor in HEPG2 cells (2003) (0)
P817 EARLY MENOPAUSAL STATUS IS ASSOCIATED WITH THE SEVERITY OF LIVER FIBROSIS IN ITALIAN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (0)
Increased prevalence of pis AlphaI-antitrypsin allele in Italian patients with non alcoholic fatty liver disease (NALFD) (2002) (0)
THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes (2019) (0)
Enrichment in novel rare coding variants of Telomerase gene in hepatocellular carcinoma patients with NASH related cirrhosis (2014) (0)
Impact of deterioration of lifestyle and PNPLA3 genotype in NALFD patients during COVID-19 lockdown (2022) (0)
Hemochromatosis in Italy in the Last 30 Years. Role of Genetic and Acquired Factors. (2009) (0)
Inherited variants of genes involved in insulin signalic and lipogenesis influence the risk of hepatic fibrosis in nonalcoholic fatty liver disease (2007) (0)
Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression in patients with NAFLD (2016) (0)
ATG7 genetic variant and defective autophagy: a novel risk factor for non-alcoholic fatty liver disease progression in patients with type 2 diabetes mellitus (2019) (0)
Mechanisms underlying hepatic iron accumulation in a dietary experimental model of NAFLD (2009) (0)
Genetic polymorphisms in subjects with Non Alcoholic Fatty Liver Disease. (2009) (0)
Cardiovascular risk assessment in alcoholic liver disease: A pilot study (2017) (0)
Circulating PCSK9 Levels are Associated with the Hepatic Fat in Non-Alcoholic Fatty Liver Disease (2016) (0)
Hypermethylation of oncosuppressor genes in hereditary hemochromatosis (2010) (0)
Iron depletion by phlebotomy improves liver transaminases in patients with nonalcoholic fatty liver disease : a propensity score adjusted analysis (2008) (0)
Corrigendum (2013) (0)
P1009 : Incidence of major cardiovascular and cerebral events in patients with NAFLD and in controls of general population during 10 years of follow up: correlation between vascular and liver damage (2015) (0)
Normal beta-2-microglobulin (β2m) gene in patients with hemochromatosis and no evidence of linkage to chromosome 6 (1998) (0)
Hepatic expression of the forkhead transcription factor Fox01 is increased in non-alcoholic steatohepatitis and associated with enhanced glucogenesis and insulin resistance (2007) (0)
Epicardial and liver fat, evaluated by ultrasound in general population and in non-alcoholic fatty liver disease (NAFLD) predict cardiovascular damage (2015) (0)
Role of nutritional intake on clinical presentation of lean and overweight NAFLD (2018) (0)
Iron and insulin resistance: Effect of iron manipulation on insulin receptor in HEPG2 hepatocytes (2003) (0)
Immunohistochemical Evaluation of a Panel of Monoclonal Antibodies for the Diagnosis of Small Cell Lung Cancer (1988) (0)
136 THE A736V TMPRSS6 POLYMORPHISM IS ASSOCIATED WITH THE PENETRANCE OF HEREDITARY HEMOCHROMATOSIS AND HEPATOCELLULAR CARCINOMA IN C282Y +/+ PATIENTS (2012) (0)
PNPLA3 I148M polymorphism, etiology, and clinical features of hepatocellular carcinoma (2011) (0)
662 Heterogeneity of iron overload: Clinical, biochemical, histopathologic and genetic study of 70 patients (2006) (0)
cell growth control modulation during cellular proliferation and potential implication in Specific binding sites for H-ferritin on human lymphocytes: (2011) (0)
PO5-118 INTERLEUKIN-6-174G/C POLYMORPHISM IS ASSOCIATED WITH INSULIN RESISTANCE IN NAFLD. A CLUE TO DISEASE SUSCEPTIBILITY? (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Silvia Fargion?

Silvia Fargion is affiliated with the following schools: